CPME Rapporteur on Health Technology Assessment: Dr Bernard MAILLET (BE)
CPME Secretariat: Ms Carole ROUAUD
Evidence-based medicine is central to CPME’s understanding of high quality healthcare. To translate scientific knowledge on medicines and devices for decision-making in medical practice, Health Technology Assessment (HTA) plays a crucial role. CPME believes that transparency of procedure and outcomes, as well as meaningful consideration of the ethical and social dimensions of technologies must be guiding principles for HTA.
Cross-border cooperation on HTA can facilitate and improve processes and thus lead to better and more accessible outcomes. CPME is member of the Stakeholder Forum of the European Network on Health Technology Assessment (EUnetHTA) Joint Action, which brings together national HTA bodies. In this framework we provide input on HTA approaches relevant to the medical profession’s point of view.
Adopted policies include:
- CPME statement on the Commission’s legislative proposal on Health Technology Assessment (HTA), April 2018
- CPME response to public consultation on strengthening EU cooperation on Health Technology Assessment (HTA) , January 2017
- CPME Statement on Health Technology Assessment in Relation to Cross-Border Healthcare, adopted in November 2011
